Cardium Therapeutics Inc. Comm (CRXM) 0.6000 $CRXM
Angina (Angina Pectoris) - Pipeline Review, H1 2014: 11 Company and 15 Drug Profiles
M2 - Wed May 07, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shfvfz/angina_angina) has announced the addition of the "Angina (Angina Pectoris) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardiolynx AG - Cardium Therapeutics, Inc. - Cheiljedang Corporation - Diakron Pharmaceuticals, Inc. - Juventas Therapeutics, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Lacer, S.A. - Mesoblast Limited - Milestone Pharmaceuticals, Inc. - ViroMed Co., Ltd. Drug Profiles: - alferminogene tadenovec - VM-202 - VM-202 - CJ-30059 - ACP-01 - Organic Nitrate For Angina Pectoris - CLC-1201 - DP-3005 - JVS-100 - CEP-41750 - LA-8045 - MSP-2017 - BAY-606583 - KI-1007 - R-06 For more information visit http://www.researchandmarkets.com/research/sh...ina_angina
Global Diabetic Foot Ulcers Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/423zx2/diabetic_foot) has announced the addition of the "Global Diabetic Foot Ulcers Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Derma Sciences, Inc. - Cardium Therapeutics, Inc. - GlaxoSmithKline plc - CardioVascular BioTherapeutics, Inc. - Stratatech Corporation - Photopharmica Limited - Tissue Med Biosciences - Reliance Life Sciences Pvt. Ltd. - Nanotherapeutics, Inc. - Celgene Corporation - Kaken Pharmaceutical Co., Ltd. - CytoTools AG - Indus Biotech Private Limited - Phage Pharmaceuticals, Inc. - NovaLead Pharma Pvt. Ltd. - FirstString Research, Inc. - Theravasc, Inc. - CoDa Therapeutics, Inc. - Adocia - EyeGene, Inc. - Izun Pharmaceuticals Corporation - Praxis Pharmaceuticals Inc. - Oneness Biotech Co., Ltd. - Aprogen, Inc. - Pergamum AB - Dipexium Pharmaceuticals LLC - Kasiak Research Pvt. Ltd. Drug Profiles - pexiganan acetate - DermaPro CI-05 - trafermin - WH-1 - DSC-127 - CVBT-141B - doxycycline - GAM-501 - Biochaperone PDGF-BB - CODA-001 - PX-070101 - ReliDerm-DT - PPA-904 - IZN-6D4 - Granexin - CSTC-1 - esmolol hydrochloride - gentamicin sulfate - GSK-1278863 - Fibroblast Growth Factor-1 - PDA-002 - TMBP-3 - coagulation factor XIVa (human) - rusalatide acetate - INDUS-820 - VLD-02 - AP-102 - Drug For Wound Healing - Stromal Cell Therapy For Diabetic Complications - EG-Decorin - Nu-2 - MT-003 - CA5-HIF Gene Therapy for Wound and Ulcers - Cathelicidin - Drug For Diabetic Foot Ulcer - LL-37 - Refaheal For more information visit http://www.researchandmarkets.com/research/42...betic_foot
Taxus Cardium Presents Year-End 2013 Financial Results And Recent Developments
PR Newswire - Tue Apr 15, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today presented highlights of financial results fiscal year ended December 31, 2013, and other recent developments.
Cardium Becomes Taxus Cardium Pharmaceuticals Group In Connection With Strategic Collaboration And Funding With Shanxi Taxus Pharmaceuticals
PR Newswire - Mon Mar 17, 8:00AM CDT
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has changed its corporate name and business to Taxus Cardium Pharmaceuticals Group Inc. in connection with its strategic collaboration and funding arrangement concluded with China-based Shanxi Taxus Pharmaceuticals Co., Ltd.
Cardium Announces Strategic Collaboration And Funding With Taxus Pharmaceuticals To Support Commercial Development Of Advanced Regenerative Therapeutics
PR Newswire - Mon Mar 03, 8:00AM CST
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has entered into a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals Co., Ltd., which is affiliated with Shenzhen Forntsea Taxus Industry Capital Management, to support the worldwide clinical and commercial development of Cardium's advanced regenerative medicine therapeutics products, including Generx® product candidate and Excellagen®, FDA-cleared advanced wound care product. The Company's name will be changed to Taxus Cardium Pharmaceuticals Group in connection with the strategic collaboration.
Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
PR Newswire - Mon Jan 27, 8:00AM CST
Cardium Therapeutics Inc. (Ticker Symbol: CRXM) reported on the Company's strategic focus on its two advanced regenerative medicine therapeutics, based on encouraging preliminary findings from its Generx® Aspire International Phase 3 registration clinical study, and data on the utility of Excellagen® for wound healing and as a biologics delivery platform.
Angina (Angina Pectoris) - Pipeline Review, H1 2014: 11 Company and 15 Drug Profiles
M2 - Wed May 07, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shfvfz/angina_angina) has announced the addition of the "Angina (Angina Pectoris) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardiolynx AG - Cardium Therapeutics, Inc. - Cheiljedang Corporation - Diakron Pharmaceuticals, Inc. - Juventas Therapeutics, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Lacer, S.A. - Mesoblast Limited - Milestone Pharmaceuticals, Inc. - ViroMed Co., Ltd. Drug Profiles: - alferminogene tadenovec - VM-202 - VM-202 - CJ-30059 - ACP-01 - Organic Nitrate For Angina Pectoris - CLC-1201 - DP-3005 - JVS-100 - CEP-41750 - LA-8045 - MSP-2017 - BAY-606583 - KI-1007 - R-06 For more information visit http://www.researchandmarkets.com/research/sh...ina_angina
Global Diabetic Foot Ulcers Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/423zx2/diabetic_foot) has announced the addition of the "Global Diabetic Foot Ulcers Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Derma Sciences, Inc. - Cardium Therapeutics, Inc. - GlaxoSmithKline plc - CardioVascular BioTherapeutics, Inc. - Stratatech Corporation - Photopharmica Limited - Tissue Med Biosciences - Reliance Life Sciences Pvt. Ltd. - Nanotherapeutics, Inc. - Celgene Corporation - Kaken Pharmaceutical Co., Ltd. - CytoTools AG - Indus Biotech Private Limited - Phage Pharmaceuticals, Inc. - NovaLead Pharma Pvt. Ltd. - FirstString Research, Inc. - Theravasc, Inc. - CoDa Therapeutics, Inc. - Adocia - EyeGene, Inc. - Izun Pharmaceuticals Corporation - Praxis Pharmaceuticals Inc. - Oneness Biotech Co., Ltd. - Aprogen, Inc. - Pergamum AB - Dipexium Pharmaceuticals LLC - Kasiak Research Pvt. Ltd. Drug Profiles - pexiganan acetate - DermaPro CI-05 - trafermin - WH-1 - DSC-127 - CVBT-141B - doxycycline - GAM-501 - Biochaperone PDGF-BB - CODA-001 - PX-070101 - ReliDerm-DT - PPA-904 - IZN-6D4 - Granexin - CSTC-1 - esmolol hydrochloride - gentamicin sulfate - GSK-1278863 - Fibroblast Growth Factor-1 - PDA-002 - TMBP-3 - coagulation factor XIVa (human) - rusalatide acetate - INDUS-820 - VLD-02 - AP-102 - Drug For Wound Healing - Stromal Cell Therapy For Diabetic Complications - EG-Decorin - Nu-2 - MT-003 - CA5-HIF Gene Therapy for Wound and Ulcers - Cathelicidin - Drug For Diabetic Foot Ulcer - LL-37 - Refaheal For more information visit http://www.researchandmarkets.com/research/42...betic_foot
Taxus Cardium Presents Year-End 2013 Financial Results And Recent Developments
PR Newswire - Tue Apr 15, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today presented highlights of financial results fiscal year ended December 31, 2013, and other recent developments.
Cardium Becomes Taxus Cardium Pharmaceuticals Group In Connection With Strategic Collaboration And Funding With Shanxi Taxus Pharmaceuticals
PR Newswire - Mon Mar 17, 8:00AM CDT
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has changed its corporate name and business to Taxus Cardium Pharmaceuticals Group Inc. in connection with its strategic collaboration and funding arrangement concluded with China-based Shanxi Taxus Pharmaceuticals Co., Ltd.
Cardium Announces Strategic Collaboration And Funding With Taxus Pharmaceuticals To Support Commercial Development Of Advanced Regenerative Therapeutics
PR Newswire - Mon Mar 03, 8:00AM CST
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has entered into a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals Co., Ltd., which is affiliated with Shenzhen Forntsea Taxus Industry Capital Management, to support the worldwide clinical and commercial development of Cardium's advanced regenerative medicine therapeutics products, including Generx® product candidate and Excellagen®, FDA-cleared advanced wound care product. The Company's name will be changed to Taxus Cardium Pharmaceuticals Group in connection with the strategic collaboration.
Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
PR Newswire - Mon Jan 27, 8:00AM CST
Cardium Therapeutics Inc. (Ticker Symbol: CRXM) reported on the Company's strategic focus on its two advanced regenerative medicine therapeutics, based on encouraging preliminary findings from its Generx® Aspire International Phase 3 registration clinical study, and data on the utility of Excellagen® for wound healing and as a biologics delivery platform.
